Enlivex Ltd.’s SEC filings document its status as an Israeli foreign private issuer with ordinary shares listed under ENLV, its clinical-stage Allocetra™ program, and its prediction markets treasury strategy centered on the RAIN token and Rain protocol.
Recent Form 6-K reports furnish current disclosures on regulatory clearances for Allocetra™ in age-related knee osteoarthritis, annual financial results, tokenized representations of the company’s ordinary shares, Rain protocol ecosystem updates, senior secured convertible debt, and the completed corporate name change from Enlivex Therapeutics Ltd. to Enlivex Ltd. The filings also reference registration statements and governance records tied to shareholder approvals and capital structure.
Enlivex Ltd. reported that the U.S. FDA has cleared its Investigational New Drug (IND) application for Allocetra™, enabling a global Phase 2b trial in patients with moderate-to-severe age-related primary knee osteoarthritis. The randomized, double-blind, placebo-controlled study will test intra-articular injections of Allocetra™ for pain, physical function, quality of life and mobility outcomes.
The company describes this as its first regulatory clearance since adopting a dual-engine strategy that combines a clinical-stage quality longevity program with a prediction markets treasury built around the RAIN protocol.
ENLV is updating an at-the-market offering: it is now offering up to $250,000,000 of ordinary shares for sale pursuant to an At-The-Market Sales Agreement with BTIG, LLC.
The supplement notes the company initially registered up to $299,553,108 under the agreement and that, from November 24, 2025 through the supplement date, the company sold an aggregate of 1,936,660 ordinary shares for aggregate gross proceeds of $2,513,111. Sales may be made from time to time in at-the-market transactions under the Sales Agreement; the offering amount here excludes shares previously sold under the Prospectus.
Enlivex Ltd. Chief Executive Officer Oren Hershkovitz filed an initial ownership report showing his current equity position in the company. He directly holds 172,855 Ordinary Shares, each with a par value of NIS 0.40.
He also holds employee stock options to acquire 150,000 Ordinary Shares at an exercise price of $8.19 per share that expire on December 31, 2033, and options to acquire an additional 60,000 Ordinary Shares at an exercise price of $5.34 per share that expire on November 17, 2032. This filing does not reflect new purchases or sales but establishes his existing holdings.
Enlivex Ltd. Chief Financial Officer Shachar Shlosberger filed an initial statement of beneficial ownership, reporting direct holdings of 139,314 Ordinary Shares, par value NIS 0.40 per share. This Form 3 also lists multiple employee stock options to buy additional Ordinary Shares at preset exercise prices.
The disclosed options cover blocks of underlying shares such as 10,000 shares at an exercise price of $3.2100 per share expiring on February 15, 2034, and 7,500 shares at $5.3400 per share expiring on March 29, 2032. Additional option positions include smaller grants at exercise prices of $2.6900, $4.6800, $6.2200 and $10.1200, with expiration dates extending through December 31, 2033. The filing reflects existing holdings only and does not show new purchases or sales.
Enlivex Ltd. director Hart Gili filed an initial ownership report showing existing equity and option positions, with no new buy or sell transactions reported. The filing lists direct ownership of 7,672 ordinary shares and two option grants over 66,489 and 3,382 underlying ordinary shares. One option has a strike price of $2.69 and expires on December 31, 2033, and another has a strike price of $5.34 and expires on November 17, 2032. A footnote states that one option grant vests in equal annual installments over four years beginning on November 17, 2023.
Enlivex Ltd. director Shai A. Novik filed an initial Form 3 reporting his beneficial ownership. He holds 6,974,017 Ordinary Shares, par value NIS 0.40 per share, directly. The filing also lists multiple option awards to buy additional ordinary shares at exercise prices between 2.6900 and 12.2300, with expirations from 2030-05-03 to 2033-12-31. This Form 3 records existing holdings and does not show new purchases or sales.
Enlivex Ltd. director Roger Pomerantz filed an initial ownership report showing his current equity position. He holds options to acquire 150,000 ordinary shares at an exercise price of $5.967 per share, vesting annually over four years beginning on November 17, 2023, and directly owns 2,480 ordinary shares.
Enlivex Ltd. director Havron Avraham filed an initial ownership report showing a direct stake in ordinary shares and stock options. He holds 183,836 ordinary shares and options over 53,192 shares at an exercise price of $2.69 expiring on December 31, 2033, plus options over 3,382 shares at $5.34 expiring on November 17, 2032. The latter option grant vests in equal annual installments over four years beginning November 17, 2023.
Enlivex Ltd. Chief Medical Officer Einat Galamidi filed an initial ownership report showing her equity stake in the company. She holds 156,304 Ordinary Shares, par value NIS 0.40 per share, directly. She also holds employee stock options over 25,000 shares at an exercise price of $5.3400 per share expiring on March 29, 2032, and options over 10,000 shares at $3.2100 per share expiring on February 15, 2034. The filing does not show any new purchases or sales, only current holdings.
Enlivex Therapeutics Ltd. has formally changed its corporate name to Enlivex Ltd. following shareholder approval at an Extraordinary General Meeting held on February 3, 2026. Shareholders authorized the new name or another name containing the word “Enlivex,” subject to approval by the Israeli Registrar of Companies.
On February 10, 2026, the Registrar of Companies in Israel issued a Certificate of Change of Name, confirming the change to Enlivex Ltd. This certificate is attached as Exhibit 99.1 and the updated name is now incorporated by reference into the company’s existing U.S. registration statements on Forms S-8 and F-3.